Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia.
Olga KraliYanara Marincevic-ZunigaGustav ArvidssonAnna Pia EnbladAnders LundmarkShumaila SayyabVasilios ZachariadisMerja HeinäniemiJanne SuhonenLaura OksaKaisa VepsäläinenIngegerd ÖfverholmGisela BarbanyAnn NordgrenHenrik LilljebjörnThoas FioretosHans O MadsenHanne Vibeke MarquartTrond FlaegstadErik ForestierÓlafur G JónssonJukka KanervaOlli LohiUlrika Norén-NyströmKjeld SchmiegelowArja HarilaMats HeymanGudmar LönnerholmAnn-Christine SyvänenJessica NordlundPublished in: NPJ precision oncology (2023)
Genomic analyses have redefined the molecular subgrouping of pediatric acute lymphoblastic leukemia (ALL). Molecular subgroups guide risk-stratification and targeted therapies, but outcomes of recently identified subtypes are often unclear, owing to limited cases with comprehensive profiling and cross-protocol studies. We developed a machine learning tool (ALLIUM) for the molecular subclassification of ALL in retrospective cohorts as well as for up-front diagnostics. ALLIUM uses DNA methylation and gene expression data from 1131 Nordic ALL patients to predict 17 ALL subtypes with high accuracy. ALLIUM was used to revise and verify the molecular subtype of 281 B-cell precursor ALL (BCP-ALL) cases with previously undefined molecular phenotype, resulting in a single revised subtype for 81.5% of these cases. Our study shows the power of combining DNA methylation and gene expression data for resolving ALL subtypes and provides a comprehensive population-based retrospective cohort study of molecular subtype frequencies in the Nordic countries.
Keyphrases
- dna methylation
- gene expression
- acute lymphoblastic leukemia
- machine learning
- randomized controlled trial
- genome wide
- big data
- metabolic syndrome
- ejection fraction
- deep learning
- young adults
- adipose tissue
- skeletal muscle
- prognostic factors
- pain management
- single cell
- chronic pain
- insulin resistance
- patient reported outcomes